Clinical Trial Update: Efficacy and Safety of Numeta G13%E Compared to Compounded Parenteral Nutrition in Preterm Neonates [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Numeta G13%E to compounded parenteral nutrition in preterm neonates has been withdrawn. The study addressed infant malnutrition and en…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enteral Feeding Intolerance
• Infant Malnutrition

Drugs mentioned

• Compounded Parenteral Nutrition
• Numeta G13%E

Snippet

Sponsor: Baxter Healthcare Corporation | Conditions: Malnutrition, Infant, Enteral Feeding Intolerance | Phase 3 | Status: WITHDRAWN